Hydralazine for essential hypertension

  • Kandler M
  • Mah G
  • Tejani A
  • et al.
33Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative effectiveness compared to placebo on surrogate and clinical outcomes is justified.

Cite

CITATION STYLE

APA

Kandler, M. R., Mah, G. T., Tejani, A. M., Stabler, S. N., & Salzwedel, D. M. (2011). Hydralazine for essential hypertension. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004934.pub4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free